Oncology Drug Development

Lucid Diligence Brief - BioPharma

Merck–SciBrunch SPR2015: A $400M Preclinical Bet | Lucid Diligence Brief

This Lucid Diligence Brief examines Merck’s licensing deal for SciBrunch’s…

by Sreyashi Paul

WCLC 2026 preview covering lung cancer treatment trends, antibody-drug conjugates, EGFR therapies, precision oncology and AI.

WCLC 2026 Preview: Emerging Lung Cancer Therapies and Competitive Trends

WCLC 2026 at a glance At IASLC-WCLC 2026, where will the next wave of…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.